Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature

Interstitial lung disease (ILD) has been reported with the use of mammalian target of rapamycin inhibitors (mTORi). The clinical and safety databases of three Phase III trials of everolimus in de novo kidney (A2309), heart (A2310), and liver (H2304) transplant recipients (TxR) were searched using a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez, Patricia, Kohler, Sven, Dimri, Seema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281397/
https://www.ncbi.nlm.nih.gov/pubmed/25580277
http://dx.doi.org/10.1155/2014/305931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281397/
https://www.ncbi.nlm.nih.gov/pubmed/25580277
http://dx.doi.org/10.1155/2014/305931

Ejemplares similares